Drug effectiveness explained: The mathematics of antiviral agents for HIV

Science Translational Medicine

Volumn 3, Issue 91, 2011, Pages

  Perelson, Alan S ^a   Deeks, Steven G ^b,c  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTEGRASE INHIBITOR; INTERFERON; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DOSE RESPONSE; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENCY; HEPATITIS C; HILL COEFFICIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; NONHUMAN; OXYGEN AFFINITY; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION; BIOLOGICAL MODEL; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; NOTE;

ANTI-HIV AGENTS; HIV; MODELS, BIOLOGICAL;

EID: 79960371691     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002656     Document Type: Review

References (23)

1. S. M. Hammer, K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron Jr., J. E. Feinberg, H. H. Balfour Jr., L. R. Deyton, J. A. Chodakewitz, M. A. Fischl, J. P. Phair, L. Pedneault, B.-Y. Nguyen, J. C. Cook, A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337, 725-733 (1997).
2. A. S. Perelson, P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, D. D. Ho, Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
3. A. Mocroft, B. Ledergerber, C. Katlama, O. Kirk, P. Reiss, A. d'Arminio Monforte, B. Knysz, M. Dietrich, A. N. Phillips, J. D. Lundgren; EuroSIDA study group, Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 362, 22-29 (2003).
4. J. Lu, S. G. Deeks, R. Hoh, G. Beatty, B. A. Kuritzkes, J. N. Martin, D. R. Kuritzkes, Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 43, 60-64 (2006).
5. L. Shen, S. A. Rabi, A. R. Sedaghat, L. Shan, J. Lai, S. Xing, R. F. Siliciano, A critical subset model provides a conceptual basis for dose-response relationships of HIV drugs. Sci. Transl. Med. 3, 91ra63 (2011).
6. S. Norton, The origins of pharmacology in the 16th century. Mol. Interv. 5, 144-149 (2005).
7. A. Hill, A new mathematical treatment of changes of ionic concentration in muscle and nerve under the action of electric currents, with a theory as to their mode of excitation. J. Physiol. 40, 190-224 (1910).
8. N. H. Holford, L. B. Sheiner, Kinetics of pharmacologic response. Pharmacol. Ther. 16, 143-166 (1982).
9. A. H. Talal, R. M. Ribeiro, K. A. Powers, M. Grace, C. Cullen, M. Hussain, M. Markatou, A. S. Perelson, Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43, 943-953 (2006).
10. L. Shen, S. Peterson, A. R. Sedaghat, M. A. McMahon, M. Callender, H. Zhang, Y. Zhou, E. Pitt, K. S. Anderson, E. P. Acosta, R. F. Siliciano, Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14, 762-766 (2008).
11. T. C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).
12. J. R. Rosé, L. M. Babé, C. S. Craik, Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J. Virol. 69, 2751-2758 (1995).
13. Z. Ambrose, J. G. Julias, P. L. Boyer, V. N. Kewalramani, S. H. Hughes, The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine. J. Virol. 80, 2578-2581 (2006).
14. Q. Dang, J. Chen, D. Unutmaz, J. M. Coffin, V. K. Pathak, D. Powell, V. N. KewalRamani, F. Maldarelli, W. S. Hu, Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways. Proc. Natl. Acad. Sci. U.S.A. 101, 632-637 (2004).
15. N. M. Dixit, A. S. Perelson, Multiplicity of human immunodeficiency virus infections in lymphoid tissue. J. Virol. 78, 8942-8945 (2004).
16. S. A. Yukl, A. K. Shergill, K. McQuaid, S. Gianella, H. Lampiris, C. B. Hare, M. Pandori, E. Sinclair, H. F. Günthard, M. Fischer, J. K. Wong, D. V. Havlir, Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 24, 2451-2460 (2010).
17. S. A. Riddler, R. Haubrich, A. G. DiRienzo, L. Peeples, W. G. Powderly, K. L. Klingman, K. W. Garren, T. George, J. F. Rooney, B. Brizz, U. G. Lalloo, R. L. Murphy, S. Swindells, D. Havlir, J. W. Mellors; AIDS Clinical Trials Group Study A5142 Team, Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358, 2095-2106 (2008).
18. M. J. Buzón, M. Massanella, J. M. Llibre, A. Esteve, V. Dahl, M. C. Puertas, J. M. Gatell, P. Domingo, R. Paredes, M. Sharkey, S. Palmer, M. Stevenson, B. Clotet, J. Blanco, J. Martinez-Picado, HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16, 460-465 (2010).
19. J. R. Arribas, A. Horban, J. Gerstoft, G. Fätkenheuer, M. Nelson, N. Clumeck, F. Pulido, A. Hill, Y. van Delft, T. Stark, C. Moecklinghoff, The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24, 223-230 (2010).
20. J. G. McHutchison, G. T. Everson, S. C. Gordon, I. M. Jacobson, M. Sulkowski, R. Kauffman, L. McNair, J. Alam, A. J. Muir; PROVE1 Study Team, Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009).
21. F. Poordad, J. McCone Jr., B. R. Bacon, S. Bruno, M. P. Manns, M. S. Sulkowski, I. M. Jacobson, K. R. Reddy, Z. D. Goodman, N. Boparai, M. J. DiNubile, V. Sniukiene, C. A. Brass, J. K. Albrecht, J. P. Bronowicki; SPRINT-2 Investigators, Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206 (2011).
22. M. Gao, R. E. Nettles, M. Belema, L. B. Snyder, V. N. Nguyen, R. A. Fridell, M. H. Serrano-Wu, D. R. Langley, J. H. Sun, D. R. O'Boyle 2nd, J. A. Lemm, C. Wang, J. O. Knipe, C. Chien, R. J. Colonno, D. M. Grasela, N. A. Meanwell, L. G. Hamann, Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96-100 (2010).
23. Funding: Portions of this work were done under the auspices of the U.S. Department of Energy under contract DE-AC52-06NA25396 and supported by NIH grants R37 AI028433, P20 RR018754, and R01 RR006555 (A.S.P.). S.G.D. was supported in part by the National Institute of Allergy and Infectious Diseases (RO1 AI087145, K24AI069994). Competing Interests: The authors declare no competing interests.